Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
Willing and able to provide informed consent [+11]
alpha-1-antitrypsin (A1AT) deficiency, Wilson disease, hemochromatosis, iron ove... [+23]